Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Genenta Science SpA ADR

Healthcare US GNTA

2.04USD
0.08(4.08%)

Last update at 2026-06-05T20:20:00Z

Day Range

1.962.20
LowHigh

52 Week Range

0.596.20
LowHigh

Fundamentals

  • Previous Close 1.96
  • Market Cap16.53M
  • Volume706408
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-6.57566M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.39

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -6.27211M -9.30989M -11.44059M -8.47776M -5.52933M
Minority interest - - - - -
Net income -6.27211M -9.30989M -11.44059M -3.62484M -5.56070M
Selling general administrative 3.90M 4.95M 5.26M 5.71M 2.30M
Selling and marketing expenses - - 5.10M - -
Gross profit -0.02697M -0.04651M -0.04170M - -
Reconciled depreciation 0.03M 0.04M 0.04M 0.00614M 0.00489M
Ebit -6.34311M -10.19969M -11.52654M -11.04399M -5.68727M
Ebitda -6.31613M -10.15318M -11.48483M -13.32454M -5.51273M
Depreciation and amortization 0.03M 0.05M 0.04M -2.28055M 0.17M
Non operating income net other - - - - -
Operating income -6.34311M -10.19969M -11.52654M -11.04399M -5.68727M
Other operating expenses 6.34M 10.20M 11.53M 11.04M 5.54M
Interest expense 0.38M - - 2.57M 0.01M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.61M 0.08M 0.31M - -
Net interest income 0.61M 0.08M 0.31M 0.04M -0.01172M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - 0.00000M -4.85292M 0.03M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 6.32M 10.15M 11.48M 11.04M 5.54M
Cost of revenue 0.03M 0.05M 0.04M - -
Total other income expense net 0.07M 0.89M 0.09M 2.57M 0.16M
Discontinued operations - - - - -
Net income from continuing ops -6.52983M -8.91249M -11.64546M -8.47776M -5.52933M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 31.89M 14.82M 22.37M 33.44M 40.03M
Intangible assets - 0.09M 0.00009M - -
Earning assets - - - - -
Other current assets 0.54M 0.36M 1.65M 0.22M 0.02M
Total liab 10.05M 2.33M 1.92M 2.30M 1.17M
Total stockholder equity 21.84M 12.50M 20.45M 31.14M 38.86M
Deferred long term liab - - - - -
Other current liab 0.61M 1.77M 1.44M 0.99M 0.95M
Common stock 84.26M 68.46M 67.40M 66.60M 65.88M
Capital stock 84.26M 68.46M 67.34M 66.60M 65.88M
Retained earnings -62.58535M -56.05552M -47.18189M -35.46556M -27.01981M
Other liab - - - 0.12M -
Good will - - - - -
Other assets - - - 1.60M -
Cash 5.53M 4.58M 3.69M 29.79M 37.24M
Cash and equivalents - - - - -
Total current liabilities 2.12M 2.10M 1.74M 2.18M 1.14M
Current deferred revenue - - - - -
Net debt 2.08M -4.56715M -3.69445M -29.79486M -37.24016M
Short term debt - 0.01M - - -
Short long term debt - - - - -
Short long term debt total 7.60M 0.01M 0.00001M - -
Other stockholder equity - - -0.00000M - -
Property plant equipment - - - - -
Total current assets 29.98M 14.47M 21.27M 31.72M 38.76M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments 22.62M 8.08M 15.10M - -
Net receivables 1.29M 1.45M 0.83M 1.56M 1.42M
Long term debt 7.60M - - - -
Inventory - - 0.00000M 0.14M 0.08M
Accounts payable 1.51M 0.32M 0.29M 1.19M 0.19M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.17M 0.09M 0.23M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.89M 0.22M 0.21M 1.60M 1.24M
Deferred long term asset charges - - - - -
Non current assets total 1.91M 0.35M 1.09M 1.72M 1.27M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -14.53631M 6.88M -14.89267M -0.02707M -0.00901M
Change to liabilities - - - 0.00000M 0.00000M
Total cashflows from investing activities -14.54394M 6.88M -14.89267M -0.02707M -0.02707M
Net borrowings 7.50M 0.00000M 0.00000M - -
Total cash from financing activities 22.29M 0.27M 0.00053M 0.00000M 28.74M
Change to operating activities - - - -0.76388M -0.76388M
Net income -6.52983M -8.91249M -11.64546M -8.47776M -5.52933M
Change in cash 0.95M 0.89M -26.10344M -7.44531M 21.77M
Begin period cash flow 4.58M 3.69M 29.79M 37.24M 15.47M
End period cash flow 5.53M 4.58M 3.69M 29.79M 37.24M
Total cash from operating activities -6.86796M -6.24017M -11.20502M -7.41824M -6.95817M
Issuance of capital stock - - 0.00053M 0.00000M 28.74M
Depreciation 0.03M 0.04M 0.04M 0.00614M 0.00489M
Other cashflows from investing activities - - -0.30499M - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities 14.79M 0.27M -14.89267M -0.02707M 0.00054M
Change to netincome - - - 0.81M 0.81M
Capital expenditures 0.00762M 0.00447M 0.01M 0.03M 0.00901M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.57897M 1.72M -0.41760M 0.24M -1.94407M
Stock based compensation 1.01M 0.85M 0.74M 0.72M 0.50M
Other non cash items 0.20M 0.06M 0.08M 0.09M 0.01M
Free cash flow -6.87558M -6.24464M -11.21881M -7.44531M -6.96718M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
GNTA
Genenta Science SpA ADR		 0.08 4.08% 2.04 - - - 0.64 -11.4756
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.

Genenta Science SpA ADR

Via Olgettina No. 58, Milan, MI, Italy, 20132

Key Executives

Name Title Year Born
Mr. Pierluigi Paracchi Vice Chairman, CEO & GM 1973
Dr. Luigi Naldini M.D., Ph.D. Co-Founder & Chairman of the Exec. Scientific Board 1959
Dr. Bernard Rudolph Gentner M.D., Ph.D. Co-Founder & Member of the Exec. Scientific Board 1975
Mr. Richard B. Slansky Chief Financial Officer 1958
Dr. Stefania Mazzoleni Ph.D. Scientific Director & Communication Officer 1981
Dr. Carlo Russo M.D. Chief Medical Officer & Head of Devel. 1953
Mr. Tim Obara Head of Bus. Devel. NA
Mr. Pierluigi Paracchi Vice Chairman of the Board, CEO & GM 1973
Dr. Luigi Naldini M.D., Ph.D. Co-Founder & Chairman of the Executive Scientific Board 1959
Dr. Bernard Rudolph Gentner M.D., Ph.D. Co-Founder & Member of the Executive Scientific Board 1975

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.